Abstract 3437
Background
Src and Vegf, targeted by D and S respectively, have been implicated in CRPC progression. Moreover the unmet need for predictive markers has become pressing. We conducted a study to determine if the addition of either agents could prolong time to progression (TTP) on AA and to test a prespecified molecular signature.
Methods
This is a phase II study of AA in bone mCRPC patients randomized upon progression to combination with D or S, comparing the two treatment strategy. Endpoints include PFS, safety, survival, assessment of aprespecified signaling signature in pts with benefit vs primary resistance to AA (progression ≤ 4 months). Pts had pretreatment bone biopsy. Tumor Markers included, Androgen Receptor-N terminal (AR-N), AR-C terminal (AR-C), CYP17, Ki67, GR, ERG, Ki67 (%), pSrc, vegf, DNA repair genes by IHC and steroids by LCMS.
Results
Study (03/2011-02/2015) accrued 179 bone mCRPC pts and median follow up 27ms (9-57). Medians: Age, 68 ys (range 45-87), PS ECOG 1 (range 0-1) baseline PSA 20.6 (range 0.5-1655). 27 (16%) pts have visceral mets, 40 (22%) prior chemo. Diagnostic Gleason Score was ≥8 in 71%. Upon progression 128/179 pts were randomized: 64 to D (AD) and 64 to S (AS). Of these 61 crossed over and 30 are still on treatment. Fifty Five pts had primary resistance to AA. Thirteen pts discontinued due to adverse events (2 AA, 6AD and 5 AS) Median (CI 95%) TTP and Overall Survival (OS) for the cohort are 12.85 (11.08, 14.98 ) and 26.26 ( 23.21, 31.93 ) ms respectively. There is no difference for drug sequence. On multivariate analysis, primary resistance to AA (p
Conclusions
D or S do not improve AA efficacy or overcome primary resistance. Validation of prespecified androgen signaling signature predictive of AA response is planned in a multi-institutional study.
Clinical trial identification
NCT01254864
Legal entity responsible for the study
MD Anderson Cancer Center
Funding
Janssen
Disclosure
E. Efstathiou: research support, ad board honoraria; Janssen, Astellas, Sanofi, Medivation, Takeda.
C. Logothetis: Research: BMS, Medivation, Sanofi, Astellas, Janssen. Advisory boards: Astellas, AstraZeneca, Janssen, Sanofi, Bayer, Medivation, Clovis, Oncology, Churchill Pharmaceuticals.
All other authors have declared no conflicts of interest.
Resources from the same session
Risk of prostate cancer mortality in men with an initial benign needle core biopsy set: a population based analysis with up to 20 years of follow-up
Presenter: Nina Klemann
Session: Genitourinary tumours, prostate
Resources:
Abstract
PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Genitourinary tumours, prostate
Resources:
Abstract
Presentation
PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Genitourinary tumours, prostate
Resources:
Abstract
Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial
Presenter: Felix Feng
Session: Genitourinary tumours, prostate
Resources:
Abstract
Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study
Presenter: Aaron Hansen
Session: Genitourinary tumours, prostate
Resources:
Abstract
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients
Presenter: Cécile Vicier
Session: Genitourinary tumours, prostate
Resources:
Abstract
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
Presenter: Wanling Xie
Session: Genitourinary tumours, prostate
Resources:
Abstract
Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
Presenter: Christopher Sweeney
Session: Genitourinary tumours, prostate
Resources:
Abstract
Invited discussant abstracts LBA29 and 719O
Presenter: Winald Gerritsen
Session: Genitourinary tumours, prostate
Resources:
Presentation
Invited discussant abstracts 725PD, 726PD, 727PD, 728PD, 729PD and 730PD
Presenter: David Olmos
Session: Genitourinary tumours, prostate
Resources:
Presentation
Webcast